MEDIPOST
MEDIPOST Raises $140M | Regenerative Medicine for Osteoarthritis
MEDIPOST Closes $140M for Stem Cell Therapy
MEDIPOST, a regenerative medicine company, has raised $140 million in late-stage private funding to advance its allogeneic stem cell therapy for knee osteoarthritis treatment.
The round was led by Skylake Equity Partners and Crescendo Equity Partners.
Key Highlights
- Focus on knee osteoarthritis treatment
- Allogeneic stem cell therapy platform
- Korean growth investor backing
Company Overview
MEDIPOST is developing regenerative medicine therapies using allogeneic stem cells, with a lead program targeting knee osteoarthritis to provide patients with alternatives to joint replacement surgery.
Company Info
Investors (2)
Share
Related Reports
Armadin Raises $255.5M Series B for Autonomous Security
Armadin raised a $255.5 million Series B co-led by Andreessen Horowitz and Accel to scale its agentic security platform and its research, training, and go-to-market efforts.
Homeward Raises $120M Series D for Cash Offer and Bridge Financing
Homeward raised a $120 million Series D led by Saluda Grade, plus $330 million in asset-backed debt, to expand cash offer and bridge financing for real estate agents.
Varda Raises $251M Series D for Space-Based Pharmaceutical Processing
Varda Space Industries raised a $251 million Series D led by Lux Capital and Natural Capital to scale space-based pharmaceutical processing.
Turn your sales ideas into reality today
Start your 14-day Pro trial today. No credit card required.
Start building for free